Surge Medical Inc.is a technology-based production enterprise focusing on real-time and rapid detection (including reagents and instruments) in the field of in vitro diagnostic reagents, a national high-tech enterprise, and a small and medium-sized enterprise of "specialized, refined, special and new" enterprises.
The company's professional and technical personnel account for 60% of the total number of the company, has a professional research and development laboratory and laboratory testing center, equipped with domestic advanced inspection and test equipment and facilities. An independent IVD production base has been established in Tonghua Pharmaceutical High-tech Zone, and the quality management system is effective and in good operation. It has longterm close cooperation with domestic key medical research departments and universities. There are two major technical platforms, colloidal gold immunochromatography and fluorescence immunochromatography. The approved products cover many fields of cardiology, gastroenterology, pediatrics, endocrinology and other fields, and have a number of invention patents and utility model patents.
In 2017,2018 and 2019, it won the "Excellence Award" of China Innovation and Entrepreneurship Competition (Jilin Division) for three consecutive years; it has undertaken 1 project of the Ministry of Science and Technology, 2 local projects guided by the central government, and 4 projects of Jilin Province independently applied by the Company. In 2021, the project with the Second Hospital of Jilin University won the first prize of Scientific Progress of Jilin Province.
Over the years, the company has insisted on research and innovation, Continued growth breakthroughs in cardiovascular and prenatal care, Relying on a strong independent research and development capability; Our company's exclusive research and production of heart marker joint test products —— "new heart damage three joint test kit" and "heart disease three test kit" has been successfully put on the market, This series complies with the guidelines and expert consensus recommendations, Covering all types of cardiac markers, It can realize heart disease warning, myocardial infarction and heart failure screening, risk stratification and prognosis assessment; Healthy birth and prenatal care series products rely on our strong research and development ability, Both the technical requirements and the diagnostic results are completely different from the marketed similar products.
After the outbreak of novel coronavirus in early 2020, Surge Medical Inc.immediately established a scientific research team with experts from the Transformation Medical School of Jilin University, and successfully developed novel Coronavirus series test kits, which shone greatly in the prevention and control of the global novel coronavirus epidemic and was recommended by the World Health Organization.
Company adhere to the "heart is good, good for good, love life, guard health" enterprise core values, determine is given priority to with POCT varieties, to become a "slow disease dynamic management expert" as the development direction of enterprises, from efforts to provide clinical frontline workers need of diagnostic tools, finally developed into all kinds of chronic disease patients with dynamic monitoring, self management of diagnosis tools professional manufacturers.
Years of research and development, focusing on the field of medical devices for many years
|
|
|
|
|
|
|
|
|
|